Is it already time for combination treatment in lower risk MDS?

The term myelodysplastic syndrome (MDS) summarizes a range of different hematological disorders, which display peripheral cytopenias as common clinical characteristic. This “ineffective hematopoiesis” is thought to be a result of an imbalance of apoptotic and proliferative signals in bone marrow cells (1).